Inventiva S.A. (NASDAQ:IVA) Short Interest Update

Inventiva S.A. (NASDAQ:IVA) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 853,400 shares, an increase of 562.1% from the September 30th total of 128,900 shares. Based on an average daily volume of 201,000 shares, the short-interest ratio is presently 4.2 days.

Inventiva Stock Up 7.3 %

Shares of Inventiva stock traded up $0.18 on Friday, hitting $2.66. The company had a trading volume of 52,505 shares, compared to its average volume of 80,913. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75. The stock has a 50-day moving average of $2.21 and a 200-day moving average of $2.75.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IVA has been the subject of several research analyst reports. HC Wainwright decreased their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. Stifel Nicolaus decreased their target price on Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and a consensus target price of $16.25.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.